Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 8/20 | 0.39 |
| ▸ | RAB9A | P51151 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855039 | 0.80 | RAB9A (0.58) | GRM1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL24491025 | 0.80 | RAB9A (0.56) | GRM1SMN1; SMN2L3MBTL1NPC1RAB9A | |
| SCHEMBL24491092 | 0.79 | GRM1 (0.43) | GRM1SMN1; SMN2L3MBTL1ADORA3RXFP1 | |
| SCHEMBL1377141 | 0.79 | ADORA3 (0.68) | GRM1SMN1; SMN2L3MBTL1ADORA3RXFP1 | |
| SCHEMBL4499496 | 0.78 | NPC1 (0.43) | SMN1; SMN2L3MBTL1NPC1RAB9ALMNA | |
| SCHEMBL3675623 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2L3MBTL1ADORA3RXFP1NPC1 | |
| SCHEMBL17667391 | 0.76 | ADORA3 (0.41) | SMN1; SMN2L3MBTL1ADORA3RXFP1NPC1 | |
| SCHEMBL9852280 | 0.75 | ALDH1A1 (0.69) | SMN1; SMN2RXFP1NPC1RAB9ALMNA | |
| SCHEMBL20971871 | 0.71 | JAK2 (0.39) | GRM1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL31110030 | 0.70 | NPC1 (0.55) | GRM1SMN1; SMN2L3MBTL1ADORA3RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426248-B1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11230543-B2 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3390357-B1 | BIARYL MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20200361928-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2020-11-19 | — | — | US | disclosed |
| US-10407421-B2 | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | MERCK SHARP & DOHME CORP (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190071436-A1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3426248-A1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180339983-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| WO-2017155765-A1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20090325956-A1 | Aromatic amine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2007-03-22 | — | — | US | disclosed |
| EP-1631558-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004103980-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339983-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | BMX, BTK, ABCB11 | GRM1 3452/4885SMN1; SMN2 3459/4885L3MBTL1 1367/4885 |
| US-10407421-B2 | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | MGAM, BMX, XDH | GRM1 2594/4885SMN1; SMN2 3231/4885L3MBTL1 455/4885 |
| US-20090325956-A1 | Aromatic amine derivative and use thereof | SCD, SCD5, SMS | GRM1 4397/4885SMN1; SMN2 2075/4885L3MBTL1 2144/4885 |
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | GRM1 403/4885SMN1; SMN2 2454/4885L3MBTL1 2773/4885 |
| US-11230543-B2 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | SQLE, ABCB11, BMX | GRM1 3621/4885SMN1; SMN2 3212/4885L3MBTL1 1267/4885 |
| US-20200361928-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | ABCB11, SQLE, BMX | GRM1 3769/4885SMN1; SMN2 3440/4885L3MBTL1 1520/4885 |
| US-20190071436-A1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, BMX, XDH | GRM1 2594/4885SMN1; SMN2 3231/4885L3MBTL1 455/4885 |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | GRM1 1890/4885SMN1; SMN2 3079/4885L3MBTL1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.